Nonclinical and early clinical development of tacrolimus ointment for the treatment of atopic dermatitis

Journal of the American Academy of Dermatology

Volumn 44, Issue 1 SUPPL., 2001, Pages

  Bekersky, Ihor ^a   Fitzsimmons, William ^a   Tanase, Atsushi ^b   Maher, Rochelle M ^a   Hodosh, Ellen ^a   Lawrence, Ira ^a  

^a ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

^b ASTELLAS PHARMA INC   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN; CORTICOSTEROID; IMMUNOMODULATING AGENT; TACROLIMUS;

ANIMAL EXPERIMENT; ARTICLE; ATOPIC DERMATITIS; BURN; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; FEMALE; HUMAN; IMMUNOMODULATION; MALE; NONHUMAN; PATCH TEST; PRIORITY JOURNAL; PRURITUS; RAT; SKINFOLD; TREATMENT OUTCOME;

EID: 0035157387     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1067/mjd.2001.109816     Document Type: Article

References (56)

1. Diagnostic features of atopic dermatitis
2. Atopic dermatitis
3. Atopic eczema: Its impact on the family and financial cost
4. The prevalence of atopic dermatitis in Oregon schoolchildren
5. New concepts in atopic dermatitis
6. Atopic dermatitis
7. Old, new, and emerging therapies for atopic dermatitis
8. New therapeutic approaches to atopic dermatitis
9. Disease management of atopic dermatitis: A practice parameter
10. A receptor for the immunosuppressant FK506 is a cis-trans peptidyl-prolyl isomerase
11. A cytosolic binding protein for the immunosuppressant FK506 has peptidylprolyl isomerase activity but is distinct from cyclophilin
12. Immunosuppressive drugs prevent a rapid dephosphorylation of transcription factor NFAT1 in stimulated immune cells
13. Direct demonstration of NFATp dephosphorylation and nuclear localization in activated HT-2 cells using a specific NFATp polyclonal antibody
14. Interaction of tacrolimus (FK506) and its metabolites with FKBP and calcineurin
15. Novel immunosuppressive agent, FK 506: In vitro effects on the cloned T cell activation
16. The immunosuppressant FK506 selectively inhibits expression of early T cell activation genes
17. Enhanced IL-5 gene transcription and allergic inflammation
18. Immunophilin ligands demonstrate common features of signal transduction leading to exocytosis or transcription
19. Anti-inflammatory effect of FK-506 on human skin mast cells
20. Characterization of the anti-inflammatory effect of FK-506 on human mast cells
21. Human basophil histamine release is differently affected by inhibitors of calmodulin, diacylglycerol kinase and peptidyl prolyl cis-trans isomerase in a secretagogue specific manner
22. Effects of cyclosporin A and FK-506 on stem cell factor-induced histamine secretion and growth of human mast cells
23. Inhibition of in vitro histamine release (HR) from human basophils by the immunosuppressive drug FK506
24. IL-13 production by peripheral blood mononuclear cells from patients with atopic dermatitis
25. Topical tacrolimus (FK-506) treatment leads to profound alterations of the antigen presenting cells in lesional atopic dermatitis skin
26. Immunosuppressive macrolides of the type FK506: A novel class of topical agents for treatment of skin diseases?
27. Anti-inflammatory effects of macrophilin-interacting drugs in animal models of irritant and allergic contact dermatitis
28. Effect of mast cell modulators on IgE-mediated murine biphasic cutaneous reactions
29. Effect of tacrolimus hydrate (FK506) ointment on spontaneous dermatitis in NC/Nga mice
30. Effects of tacrolimus ointment on type I (immediate and late) and IV (delayed) cutaneous allergic reactions in mice
31. Differential inhibition of cutaneous T-cell-mediated reactions and epidermal cell proliferation by cyclosporin A. FK506, and rapamycin
32. Topical FK506 suppresses cytokine and costimulatory molecule expression in epidermal and local draining lymph node cells during primary skin immune responses
33. Diet-induced dermatitis response of hairless rats to systemic treatment with cyclosporin A (Sandimmun), cyclosporin H, and FK5C16
34. Comparison of FK506 (tacrolimus) and glucocorticoid ointment on dermal atrophogenicity in rats
35. Percutaneous penetration in the hairless dog, weanling pig and grafted athymic nude mouse: Evaluation of models for predicting skin penetration in man
36. The permeability of skin to molecules of widely-differing properties
37. Percutaneous toxicity
38. Porcine models in surgical research
39. An evaluation of the phototoxicity of tacrolimus (FK506) ointment in hairless mice
40. Topical application of tacrolimus ointment did not alter cutaneous pigmentation of Yucatan micropigs
41. Topical triamcinolone and tacrolimus differ in their in vivo effects on Langerhan's cells during the treatment of atopic dermatitis
42. Tacrolimus ointment does not affect collagen synthesis: Results of a single-center randomized trial
43. Tacrolimus (FK506) ointment for atopic dermatitis: A phase I study in adults and children
44. A safety study of FK 506 ointment in patients with atopic dermatitis
45. Tacrolimus concentrations in blood during topical treatment of atopic dermatitis
46. A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children
47. Use of tacrolimus ointment in 3-6 year-olds with atopic dermatitis: Dose escalation study
48. Tacrolimus ointment for adults with moderate to severe atopic dermatitis: A dose escalation study
49. A short-term trial of tacrolimus ointment for atopic dermatitis
50. Early Phase II study of FK506 ointment in atopic dermatitis
51. Tacrolimus ointment for atopic dermatitis
52. A late Phase II study to determine the concentration of FK506 (tacrolimus) ointment in atopic dermatitis (Part 1): Revised version
53. A late Phase II study to determine the concentration of FK506 (tacrolimus) ointment in atopic dermatitis (Part 2)
54. Phase III comparative study of FK506 ointment vs betamethasone valerate ointment in atopic dermatitis (trunk/extremities)
55. Phase III comparative study of FK506 ointment vs alclometasone dipropionate ointment in atopic dermatitis (face and neck)
56. Comparative study of FK506 (tacrolimus) ointment vs. alclometasone dipropionate ointment in atopic dermatitis (face and neck lesions)